These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 31050315)

  • 21. Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients in a Single Center.
    Chen C; Xu H; Song K; Zhang Y; Zhang J; Wang Y; Sheng X; Chen L; Qin Z
    J Clin Med; 2022 Oct; 11(19):. PubMed ID: 36233722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States.
    Messali A; Hay JW; Villacorta R
    Neuro Oncol; 2013 Nov; 15(11):1532-42. PubMed ID: 23935155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subgroup economic analysis for glioblastoma in a health resource-limited setting.
    Wu B; Miao Y; Bai Y; Ye M; Xu Y; Chen H; Shen J; Qiu Y
    PLoS One; 2012; 7(4):e34588. PubMed ID: 22511951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
    Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
    J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for patients with newly diagnosed glioblastoma: patterns of progression in a single institution pilot study.
    Ali AS; Lombardo J; Niazi MZ; Miller RC; Alnahhas I; Martinez NL; Andrews DW; Judy KD; Shi W
    J Neurooncol; 2022 Nov; 160(2):345-350. PubMed ID: 36355259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients.
    Mehta M; Wen P; Nishikawa R; Reardon D; Peters K
    Crit Rev Oncol Hematol; 2017 Mar; 111():60-65. PubMed ID: 28259296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma.
    Lazaridis L; Schäfer N; Teuber-Hanselmann S; Blau T; Schmidt T; Oster C; Weller J; Tzaridis T; Pierscianek D; Keyvani K; Kleinschnitz C; Stuschke M; Scheffler B; Deuschl C; Sure U; Herrlinger U; Kebir S; Glas M
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):787-792. PubMed ID: 31828428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma.
    Bernard-Arnoux F; Lamure M; Ducray F; Aulagner G; Honnorat J; Armoiry X
    Neuro Oncol; 2016 Aug; 18(8):1129-36. PubMed ID: 27177573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
    Taphoorn MJB; Dirven L; Kanner AA; Lavy-Shahaf G; Weinberg U; Taillibert S; Toms SA; Honnorat J; Chen TC; Sroubek J; David C; Idbaih A; Easaw JC; Kim CY; Bruna J; Hottinger AF; Kew Y; Roth P; Desai R; Villano JL; Kirson ED; Ram Z; Stupp R
    JAMA Oncol; 2018 Apr; 4(4):495-504. PubMed ID: 29392280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma.
    Song A; Bar-Ad V; Martinez N; Glass J; Andrews DW; Judy K; Evans JJ; Farrell CJ; Werner-Wasik M; Chervoneva I; Ly M; Palmer JD; Liu H; Shi W
    J Neurooncol; 2020 May; 147(3):653-661. PubMed ID: 32206976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concurrent Tumor Treating Fields (TTFields) and Radiation Therapy for Newly Diagnosed Glioblastoma: A Prospective Safety and Feasibility Study.
    Bokstein F; Blumenthal D; Limon D; Harosh CB; Ram Z; Grossman R
    Front Oncol; 2020; 10():411. PubMed ID: 32373508
    [No Abstract]   [Full Text] [Related]  

  • 33. Cost-Effectiveness of Short-Course Radiation Plus Temozolomide for the Treatment of Newly Diagnosed Glioblastoma Among Elderly Patients in China and the United States.
    Chen J; Tong X; Han M; Zhao S; Ji L; Qin Y; He Z; Pan Y; Wang C; Liu A
    Front Pharmacol; 2021; 12():743979. PubMed ID: 34646141
    [No Abstract]   [Full Text] [Related]  

  • 34. Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma.
    Miller R; Song A; Ali A; Niazi M; Bar-Ad V; Martinez N; Glass J; Alnahhas I; Andrews D; Judy K; Evans J; Farrell C; Werner-Wasik M; Chervoneva I; Ly M; Palmer J; Liu H; Shi W
    Front Oncol; 2022; 12():896246. PubMed ID: 35574391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme.
    Uyl-de Groot CA; Stupp R; van der Bent M
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):235-41. PubMed ID: 19527095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
    Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
    J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complete radiological response following subtotal resection in three glioblastoma patients under treatment with Tumor Treating Fields.
    Kessler AF; Linsenmann T; Westermaier T; Wolber W; Weiland J; Monoranu CM; Breun M; Hagemann C; Ernestus RI; Löhr M
    Oncol Lett; 2020 Jan; 19(1):557-561. PubMed ID: 31897171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis of the addition of bevacizumab to temozolomide therapy for the treatment of unresected glioblastoma.
    Chen Z; Zhan M; Tian F; Xu T
    Oncol Lett; 2020 Jan; 19(1):424-430. PubMed ID: 31897155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progress and prospect in tumor treating fields treatment of glioblastoma.
    Liu S; Shi W; Zhao Q; Zheng Z; Liu Z; Meng L; Dong L; Jiang X
    Biomed Pharmacother; 2021 Sep; 141():111810. PubMed ID: 34214730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Efficacy of Tumor Treating Fields for Newly Diagnosed Glioblastoma.
    Liu Y; Strawderman MS; Warren KT; Richardson M; Serventi JN; Mohile NA; Milano MT; Walter KA
    Anticancer Res; 2020 Oct; 40(10):5801-5806. PubMed ID: 32988908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.